Data Quality SLAs in CRO and CDMO Contracts: Language That Actually Holds

The Accountability You Cannot Outsource

The regulatory position is not ambiguous, and it has not changed in decades. Under United States regulations governing investigational new drug applications, a sponsor may transfer responsibility for any or all of its obligations to a contract research organization, and any such transfer must be described in writing. If not all obligations are transferred, the writing must describe each obligation the CRO is assuming.¹ A CRO that assumes an obligation becomes subject to the same regulatory action as a sponsor for failure to comply with that obligation. What the regulation does not do is release the sponsor from the consequences. The sponsor still holds the application. The sponsor still submits the data. The sponsor still receives the deficiency letter.

The revised good clinical practice guideline, ICH E6(R3), makes this sharper. It introduces the broader term “service provider” to cover every third party performing trial-related activities, and it adds a dedicated treatment of data governance across the full data lifecycle: capture, processing, transfer, retention, and destruction.² Sponsors are expected to define expectations for service providers, oversee performance, and maintain visibility into data integrity and traceability even when the systems belong to someone else. Delegation of the activity is permitted. Delegation of the responsibility is not.

On the manufacturing side the same logic applies through different language. European Union GMP Chapter 7 requires a written contract between the contract giver and the contract acceptor that clearly establishes the duties of each party, and it obliges the contract giver to assess the competence of the acceptor before outsourcing anything.³ The contract must describe who is responsible for each step, and it must permit the contract giver to audit the outsourced activities. The United Kingdom regulator is more direct about data specifically: responsibilities of the contract giver and acceptor should be defined in a technical agreement, and that agreement should ensure timely access to data, including metadata and audit trails, for the data owner and for national competent authorities on request.⁴

What inspectors actually find

The gap between the regulatory expectation and the contractual reality shows up in inspection outcomes. The European Medicines Agency’s GCP Inspectors Working Group reported 67 inspections during 2024, producing 335 major and critical findings.⁵⁶ The two largest finding categories were essential documents and direct access, with 41 findings, and source documentation, with 38 findings.⁶ Both categories turn on the same underlying question: do the records exist, are they complete, and can they be reached by the people entitled to see them. That is a contracting question as much as a quality one.

Two things follow from this. First, the sponsor is the party with the strongest interest in data quality and usually the weakest instrument for enforcing it. Second, most of the enforcement happens through a document that was never designed to enforce anything. That document is the quality agreement, and understanding its limits is where a workable set of data quality provisions begins.

Where Data Terms Belong: MSA, Quality Agreement, or SOW

Sponsors routinely write data quality expectations into the wrong document. The consequence is not academic. A well-drafted obligation sitting in the wrong instrument can be unenforceable, can expire early, or can be quietly overridden by a precedence clause nobody read.

The FDA’s guidance on quality agreements in contract manufacturing is explicit that a quality agreement should not cover general business terms such as confidentiality, pricing, delivery terms, or limits on liability and damages, and it recommends that quality agreements be separate documents, or at least severable, from commercial contracts such as master services and supply agreements.⁷ That guidance is sound. It also creates a trap. If the quality agreement is where the data obligations live and the quality agreement deliberately carries no remedies, then the obligations have no consequences attached to them.

The workable split is to treat the three documents as doing three different jobs.

The precedence clause that quietly undoes your quality terms

Most master services agreements contain an order of precedence: in the event of conflict, the master agreement prevails over the quality agreement, which prevails over the statement of work. Providers propose it as boilerplate and sponsors accept it as boilerplate. The effect is that a commercial limitation in the master agreement can override a quality obligation in the quality agreement, and neither quality unit will notice until there is a dispute.

Do not let the obligations expire with the work order

The second structural error is placing durable obligations in a statement of work. Work orders close. When a study completes and the work order is closed out, an obligation to retain records for 25 years, or to provide audit trails to an inspector, or to return data on request, needs to still be live. Put the durable obligations in the master agreement with an explicit survival clause listing them by section number, and use the work order only for study-specific numbers.

Defining a Data Defect So It Can Be Counted

Every enforceable data quality provision rests on a definition. If the contract does not say what a defect is, no threshold can be measured, no remediation window can start, and no escalation can be triggered. In practice this is the single most common omission. Agreements refer to data being “accurate and complete” or delivered “in accordance with good industry practice,” which is a standard nobody can test and no arbitrator will apply cleanly.

A usable definition does three things. It ties the defect to a written specification rather than to a general standard. It covers metadata and traceability, not just values. And it separates severity classes so that remedies can be proportionate.

Notice what the definition depends on. It refers to a Data Specification and a Data Validation Plan, which means both documents have to exist, be attached as schedules, and be under change control. That is a feature. A sponsor who cannot produce a data specification cannot reasonably hold a provider to one, and the drafting exercise forces the sponsor’s own data management function to write down what it expects before the study starts.

Severity classes

Severity should follow regulatory consequence, not technical difficulty. A missing character in a comment field and a mismatched primary endpoint value are not the same event and should not attract the same remedy.

The repeat defect rule matters more than it looks. Providers manage individual defects well. What sponsors struggle to address is the same failure recurring across studies or campaigns because the underlying process was never corrected. Automatic escalation on recurrence gives the sponsor a contractual hook for a problem that is otherwise only visible in a trend report nobody acts on.

Clause Library One: Definitions, Thresholds, and Measurement

With definitions in place, the acceptance provisions become straightforward to write. The pattern is: a threshold expressed as a number, a measurement method that says who checks and how, and an acceptance mechanism that says what happens when the check is passed or failed.

Acceptance thresholds

Three drafting points. First, zero for critical defects is defensible and providers generally accept it, because the alternative is asking a provider to argue that some tolerance for wrong endpoint data is reasonable. Second, express major and minor thresholds as a rate rather than an absolute count, so the threshold scales with study size. Third, tie acceptance to the milestone. The moment a data quality threshold is linked to whether a payment milestone has been achieved, it stops being an aspiration and becomes a term the provider’s finance function tracks.

Measurement: who checks, how much, and with what access

A threshold without a measurement method is unenforceable, because the parties will disagree about the denominator. Specify the sampling approach, the fields that get complete review, and the access the sponsor needs to perform the check.

The last sentence carries most of the weight. Without it, the provider can argue that a sample finding says nothing about the population, and the sponsor is left funding a complete review to prove a point it has already demonstrated. Shifting that burden is a reasonable ask and one that most providers will concede in exchange for a defined sample size they can plan around.

The data specification obligation

Both parties benefit from a clause requiring the specification itself to exist and to be controlled. This is where sponsors should accept a reciprocal obligation, because provider redlines on data quality almost always come back to specification instability.

Giving the provider that carve-out costs the sponsor little and buys credibility for every other provision in the section. It also creates internal pressure on the sponsor’s own teams to stop changing specifications mid-study, which is frequently the actual root cause of the data problems the sponsor is trying to contract its way out of. Our work on data contracts between producers and consumers covers the internal version of the same discipline.

Clause Library Two: Remediation, Escalation, and Remedies

This is where most data quality provisions fail, and it is worth being blunt about why. The default remedy in service contracts is a service credit: the provider refunds a percentage of fees when a service level is missed. Service credits work for commodity services where the harm is proportional to the outage. They are close to worthless for data.

Why service credits do not work here

If a submission dataset arrives late or wrong, the harm to the sponsor is a delayed filing, a rework cycle across biostatistics and regulatory affairs, and in the worst case a deficiency question from an agency. A credit of five or ten percent against the data management fee for that month does not touch any of that. Worse, service credit regimes are often drafted as the sole and exclusive remedy for performance failures, which means accepting a small credit can extinguish the sponsor’s right to anything else. Commercial practice recognizes the problem: where service credits are small, or where the buyer has to ask for them, providers absorb them as a cost of doing business and chronic underperformance persists, which is why buyers with real negotiating strength push for expanded credit tiers, removal of the sole-remedy limitation for specified breach categories, and tight termination rights for chronic failure.⁸

Remedies that actually change behavior

Design remedies around three outcomes: getting the data fixed quickly, making recurrence expensive for the provider, and preserving the sponsor’s ability to leave. In rough order of how often they are accepted in negotiation:

The escalation ladder

Termination is the remedy nobody wants to use, which is exactly why the ladder leading up to it matters. A defined escalation path gives both sides a way to fix a systemic problem before the relationship reaches a decision point, and it creates the written record that supports termination if the problem is not fixed.

Audit and Inspection Rights Over Data Systems

Audit rights in most outsourcing agreements were written for facilities. They permit the sponsor to visit a site, review procedures, and inspect records on a defined notice period. They rarely extend to the computerized systems where the data is generated, processed, and stored, and they almost never address the provider’s own subcontractors and hosting arrangements.

That gap is now inconsistent with regulatory direction on both sides of the Atlantic. The draft revision of EU GMP Annex 11, published for consultation in July 2025, expands the guideline substantially and states that the regulated user remains responsible for quality and compliance even when using outsourced services including cloud platforms, requiring formal agreements with clear statements of third-party responsibilities and risk-based decisions about supplier audits.⁹ The concept paper that preceded the revision set out the same direction, noting that the original 2011 text predates current outsourcing and hosting models.¹⁰ On the clinical side, the FDA’s 2024 final question-and-answer guidance on electronic systems, electronic records, and electronic signatures in clinical investigations broadened its scope from systems “owned or controlled by” a regulated entity to systems “deployed by” one, and addresses information technology service providers directly.¹¹¹²

What to ask for

The for-cause trigger is the part worth defending in negotiation. Scheduled audits find process problems. Unscheduled audits after a defect find the specific thing that went wrong, and the right to conduct one changes provider behavior even when the sponsor never exercises it.

Regulatory inspection support

Access to data is a regulatory expectation, not just a commercial preference. The UK data integrity guidance states that the technical agreement should ensure timely access to data, including metadata and audit trails, both for the data owner and for competent authorities on request, and that contracts should define responsibility for archiving and continued readability throughout the retention period.⁴ United States CGMP records regulations require that records be readily available for authorized inspection at the establishment where the activity occurred, with records retrievable electronically from another location treated as meeting the accessibility requirement.¹³ Sponsor recordkeeping obligations for investigational drugs sit alongside those requirements.¹⁴

Subcontractor flow-down

Providers subcontract. Electronic data capture platforms, central laboratories, hosting providers, statistical programming groups, and analytical testing laboratories all sit behind the primary relationship. Regulators expect due diligence to reach them. PIC/S guidance on data management and integrity notes that summary reports from contract laboratories are limited and often exclude supporting data and metadata, so the outsourcing organization must assess the contract facility’s quality system and data integrity program and be able to conduct on-site audits where appropriate.¹⁵ An FDA warning letter issued to a contract testing laboratory in February 2025 set out the agency’s position that a contract facility operates as an extension of its clients’ operations and carries full CGMP responsibility for the data it produces.¹⁶

The list obligation is small and frequently decisive. Many sponsors discover the actual location of their trial data only when a data protection question arises or a hosting provider has an outage. Where personal data is involved, processor obligations under data protection law already require the processor to obtain authorization before engaging another processor and to impose equivalent obligations on it, which gives the sponsor a second basis for the same ask.¹⁷

Data Return, Escrow, and Continuity at Termination

Exit provisions are negotiated last, when everyone is tired, and they are the provisions sponsors regret most. The failure pattern is consistent: the contract entitles the sponsor to “its data” without saying in what form, by when, with what metadata, or at whose expense. The sponsor then receives an extract in a proprietary structure, without audit trails, without the configuration records needed to explain how values were derived, and with a bill for the extraction work.

Commercial practice outside life sciences is ahead of the industry here. Exit clauses in technology contracts increasingly specify the format and timeline for data return and note that a non-proprietary structured format is materially more useful than a proprietary schema, and that where data is to be returned in any format other than as-is, the parties should agree the format in writing in advance rather than at exit.¹⁸ Life sciences adds requirements that most technology exit clauses omit: audit trails, retention periods measured in decades, and the obligation to keep records readable for the whole of that period.

Two elements in that clause do most of the work. The requirement for derivation documentation prevents the situation where a sponsor holds numbers it cannot explain to an inspector. The prohibition on conditioning delivery on disputed payment stops a provider from holding data back to gain an advantage in a commercial dispute, which is the moment a sponsor most needs it.

Retention, destruction, and the conflict between them

Return and deletion are not the same obligation and they can conflict. Data protection law pushes toward deletion or return at the end of processing. GxP retention obligations push toward keeping records for long periods, and quality agreements typically assign archiving responsibility to whichever party generated the record. Resolve the conflict in the contract rather than at exit.

When escrow is the right ask

Escrow is worth negotiating in a narrow set of situations rather than as a standard term. It is appropriate where the sponsor’s data sits in a platform the provider licenses from a third party, where the provider is small or financially fragile, or where the data cannot be reconstructed from any other source. Escrow arrangements for hosted services have moved beyond source code deposits to include the configuration, data, and operational documentation needed to keep a service running or to move it, and providers of these arrangements now market them specifically for software delivered as a service.¹⁹

What Survives Redlining: The Negotiating Reality

A CRO or CDMO will resist open-ended data quality obligations, and the resistance is not unreasonable. Providers price work against a defined scope. An obligation whose boundary depends on the sponsor’s later judgment is an unpriced risk, and a provider that accepts many of them either raises price or discovers the problem during delivery. Sponsors who understand which asks are genuinely reasonable get further than sponsors who send a maximalist redline and negotiate down.

The pattern below reflects how these negotiations usually resolve. It is a starting position, not a prediction, and it shifts with the relative size of the parties and the length of the relationship.

Three moves that make the whole package easier to agree

Accept reciprocal obligations. The provider’s most common and most legitimate complaint is that data quality failures often start with the sponsor: late specifications, mid-study changes, slow query responses, unclear derivation rules. Writing sponsor obligations into the same section, with the same specificity, converts the discussion from a one-sided imposition into a shared standard. It also improves sponsor behavior, which improves the data.

Scope by criticality rather than by volume. A provider asked to guarantee quality across every field in a study will price for it or refuse. A provider asked to guarantee zero critical defects on a defined list of critical fields, with sampled review elsewhere, is being asked something it can actually manage. Identifying critical data fields before contracting is work the sponsor should be doing anyway. Our data quality scorecard for regulatory submissions is a reasonable starting point for that classification.

Pay for the measurement. Metrics reporting, audit trail review, and defect trending take provider effort. Sponsors who treat them as free and expect them to be absorbed usually receive a template report assembled the day before the governance meeting. Sponsors who price the reporting as a line item receive something the provider staffs. The amount involved is small next to the effort of discovering a systemic data problem at database lock.

Putting the Clause Library Into Practice

Contract language only helps if it connects to something the organization actually does. A sponsor with excellent data quality clauses and no capability to measure conformance has bought a set of rights it cannot exercise. The sequence below is the one we see work.

Governance sits over all of it. The quality agreement should name the joint review body, its membership by role, and its meeting frequency, and the data quality metrics should be a standing agenda item rather than an exception report. The same discipline that applies to third-party risk management across vendor relationships applies here, with the difference that data quality can be counted and most other risk categories cannot.

Conclusion

The asymmetry at the center of outsourcing is not going away. Sponsors will keep contracting out execution because the alternative is building capacity they do not need permanently, and regulators will keep holding sponsors accountable for the data that results. What can change is whether that asymmetry is managed in the contract or discovered during an inspection. Managing it does not require an adversarial relationship with a provider. It requires that a data defect has a definition, that acceptance has a number, that correction has a deadline, that audit rights reach the systems and not just the buildings, and that the data comes back in a usable form when the relationship ends.

The sponsors who do this well are not the ones with the longest contracts. They are the ones who decided, before the first work order, which data carries regulatory consequence, wrote the specification, put the durable obligations in the master agreement where they survive, kept the quality agreement focused on quality, and fixed the precedence clause so the two documents work together. The drafting itself is a few pages. The preparation behind it is where the value sits, and most of that preparation is work a quality and data organization benefits from regardless of who is doing the execution.

Sakara Digital works with pharma and biotech organizations building this kind of oversight into their outsourcing relationships, from classifying critical data through to the contract language and the metrics that make it enforceable. If you are reviewing a CRO or CDMO agreement and want an independent perspective on where the gaps are, we are happy to have that conversation.

For Further Reading